Glenmark Pharmaceuticals, Inc., USA said it has entered into a strategic Development, License and Commercialization Agreement with Particle Sciences, Inc. to develop and market a generic version of Celgene’s Abraxane, used for cancer treatment.
As per the terms of the agreement, Glenmark has obtained global exclusive marketing and distribution rights of the product upon commercialization.
Particle Sciences, part of Lubrizol LifeSciences, is an integrated provider of drug development services and is based in Bethlehem, Pennsylvania.
Abraxane marketed globally by Celgene has reported sales of USD 967 million world-wide and USD 654 million in the USA in the calendar year 2015. It is paclitaxel protein (albumin)-bound particles for injectable suspension.
¨Particle Sciences will develop this product exclusively for Glenmark, and shall receive certain milestone payments during various stages of the product’s development from Glenmark, including royalties on sales. Development of the product has been initiated for the USA market and Glenmark intends to file the ANDA in FY19. The product will be subsequently filed in other key markets across the globe,¨ the Indian company said.
“The partnership is a significant development in Glenmark’s complex generics strategy and we are pleased to
collaborate with Particle Sciences given their strong technical capabilities and understanding of particulate
injection products. This is a challenging product to develop and we expect it to remain a limited competition
opportunity,” said Robert Matsuk, President – North America and Global API, Glenmark Pharmaceuticals
Limited.
Abraxane is used for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. It can also be used for non-small cell lung cancer (NSCLC), as first-line treatment and in pancreatic cancer treatment.
Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical organization
headquartered at Mumbai, India.